VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.45%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$3.44M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$670K |
| 2 |
Zai Lab
ZLAB
|
$520K |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$422K |
| 4 |
DRD
DRDGold
DRD
|
$405K |
| 5 |
Stellus Capital Investment Corp
SCM
|
$402K |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$1.28M |
| 2 |
Prothena Corp
PRTA
|
$971K |
| 3 |
BioNTech
BNTX
|
$787K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$647K |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$645K |
Sector Composition
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NSL
126
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $538K | 0.22% |
91,006
+24,795
| +37% | +$147K |
|
127
BlackRock Debt Strategies Fund
DSU
$547M
| $535K | 0.22% |
46,713
+13,290
| +40% | +$152K |
|
128
Bain Capital Specialty
BCSF
$1.02B
| $533K | 0.22% |
34,822
+7,007
| +25% | +$107K |
|
129
Gladstone Investment Corp
GAIN
$543M
| $532K | 0.22% |
36,950
+5,100
| +16% | +$73.4K |
|
130
Ligand Pharmaceuticals
LGND
$3.25B
| $532K | 0.22% |
6,503
-3,351
| -34% | -$274K |
|
131
Ionis Pharmaceuticals
IONS
$9.76B
| $527K | 0.22% |
13,212
+128
| +1% | +$5.11K |
|
132
Regeneron Pharmaceuticals
REGN
$60.8B
| $527K | 0.22% |
944
-303
| -24% | -$169K |
|
133
ADC Therapeutics
ADCT
$398M
| $524K | 0.22% |
21,540
+12,764
| +145% | +$311K |
|
|
MCI
134
Barings Corporate Investors
MCI
$434M
| $524K | 0.22% |
34,476
+5,714
| +20% | +$86.8K |
|
135
Halozyme
HALO
$8.76B
| $523K | 0.22% |
11,515
-3,439
| -23% | -$156K |
|
|
136
Zai Lab
ZLAB
$3.42B
| $520K | 0.21% |
+2,937
| New | +$520K |
|
137
Nuveen Floating Rate Income Fund
JFR
$1.13B
| $519K | 0.21% |
51,821
+14,649
| +39% | +$147K |
|
138
Vertex Pharmaceuticals
VRTX
$102B
| $517K | 0.21% |
2,563
-176
| -6% | -$35.5K |
|
|
JRO
139
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
| $514K | 0.21% |
52,698
+14,838
| +39% | +$145K |
|
|
BPMC
140
DELISTED
Blueprint Medicines
BPMC
| $509K | 0.21% |
5,786
+452
| +8% | +$39.8K |
|
141
Alnylam Pharmaceuticals
ALNY
$59.2B
| $508K | 0.21% |
2,996
-1,725
| -37% | -$292K |
|
142
Incyte
INCY
$16.9B
| $508K | 0.21% |
6,042
-1,162
| -16% | -$97.7K |
|
|
143
BioNTech
BNTX
$27B
| $507K | 0.21% |
2,264
-3,515
| -61% | -$787K |
|
|
DCPH
144
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $507K | 0.21% |
13,846
+2,867
| +26% | +$105K |
|
145
Amgen
AMGN
$153B
| $505K | 0.21% |
2,070
-680
| -25% | -$166K |
|
146
BioMarin Pharmaceuticals
BMRN
$11.1B
| $505K | 0.21% |
6,054
-1,496
| -20% | -$125K |
|
|
ALXN
147
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $505K | 0.21% |
2,749
-1,260
| -31% | -$231K |
|
148
Gilead Sciences
GILD
$143B
| $504K | 0.21% |
7,326
-3,252
| -31% | -$224K |
|
|
SGEN
149
DELISTED
Seagen Inc. Common Stock
SGEN
| $504K | 0.21% |
3,195
-34
| -1% | -$5.36K |
|
150
Karyopharm Therapeutics
KPTI
$57.2M
| $500K | 0.21% |
3,229
+550
| +21% | +$85.2K |
|